December 29, 2025
Because Genome BC invested in a blood-based biomarker, patients with autoimmune disease may soon get answers faster.
Autoimmune diseases like rheumatoid arthritis can take years to diagnose and treat effectively. Augurex Life Sciences is changing that — with a simple blood test that identifies the 14-3-3η protein, a biomarker associated with disease activity and progression.
With early-stage investment from Genome BC, Augurex was able to validate and commercialize the test, now licensed globally and used by specialists in over 20 countries. This breakthrough means earlier diagnosis, better monitoring and more personalized care for patients living with chronic autoimmune conditions.
Led by Norma Biln, Augurex exemplifies BC’s strength in biotech diagnostics, where targeted innovation leads to actionable insights. Genome BC’s early support helped advance a powerful idea from lab to clinical use.
Faster answers. Better outcomes. Proof that BC is leading in life-changing diagnostics.
